A day-to-day management model improves patient compliance to treatment for Helicobacter pylori infection: a prospective, randomized controlled study

Zhen Yang, Wenjie Xiong, Ruoyun Yang, Haisheng Qian, Zhiqing He, Meihong Chen, Jiajia Yang, Huaiming Sang, Yan Jin, Xiaobing Xu, Yun Wang, Guoxin Zhang, Feng YeGut 2023 · DOI

TL;DR

Researchers have developed a "day-to-day" (DTD) management model integrated into WeChat to help patients stick to the complex 14-day medication regimen required to treat Helicobacter pylori. The study found that this self-monitoring approach significantly boosted medication adherence and follow-up rates compared to standard education, effectively turning a grueling pill schedule into a manageable daily habit without requiring extra work from doctors.

What Problem Does This Paper Address?

Helicobacter pylori (H. pylori) is a bacterium that infects roughly half the world's population and is a leading cause of peptic ulcers and gastric cancer. Eradicating it is vital, but the treatment is notoriously difficult for patients to complete. It typically involves "quadruple therapy": four different medications taken at specific intervals (some before meals, some after) for 14 days.

Poor compliance is the primary reason treatment fails, which in turn fuels antibiotic resistance. While previous interventions have used text message reminders or phone calls, these are often "passive" for the patient and labor-intensive for healthcare providers. The authors sought to test whether a "day-to-day" model—focused on active goal-setting and habit formation—could improve outcomes.

Methods

The researchers conducted a single-center, prospective, randomized controlled trial (RCT) involving 254 patients in China. Patients were split into two groups:

  1. Conventional Outpatient Education (OE): Received verbal and written instructions and a manual.
  2. Day-to-Day (DTD) Management: Received the same education plus access to a WeChat-based tool.

The DTD model required patients to actively engage:

  • Step 1: Click a "Start medication" button to begin the 14-day clock.
  • Step 2: Click a "Finish taking medication" button each day after completing their doses.
  • Visual Feedback: The app displayed a calendar where completed days turned blue with a checkmark, providing a visual "completion flag" to motivate the patient.
  • Automatic Follow-up: Once the 14 days ended, the system automatically calculated and displayed the date for the mandatory follow-up urea breath test (UBT).

Datasets

As a clinical trial, the "dataset" consists of the patient cohort.

  • Participants: 254 H. pylori-positive patients (127 per group).
  • Location: First Affiliated Hospital of Nanjing Medical University, China.
  • Metrics: The study tracked medication compliance (taking >80% of pills), follow-up compliance (returning for a breath test 1–2 months later), and the actual eradication rate of the bacteria.

Key Insights and Ideas

  • Active vs. Passive Engagement: Unlike simple SMS reminders, the DTD model requires the patient to "check in." This shift from being a passive recipient of a reminder to an active participant helps facilitate habit formation.
  • The Power of the "Completion Flag": The visual satisfaction of seeing a calendar fill with checkmarks acts as a psychological nudge, encouraging patients to maintain their "streak."
  • Closing the Follow-up Loop: A major hurdle in H. pylori treatment is that patients often feel better and forget to return for the follow-up test to confirm the bacteria are gone. The DTD model’s automatic calculation of the re-test date significantly improved return rates.
  • Reducing Physician Burden: Because the model is integrated into a social media platform (WeChat) and is largely automated, it improves patient behavior without requiring doctors to spend hours on the phone or sending manual messages.

Key Results

The study analyzed results using Intention-to-Treat (ITT), which includes everyone who started the study, and Per-Protocol (PP), which only includes those who finished.

  • Medication Compliance: In the ITT analysis, the DTD group showed 95.3% compliance compared to 78.7% in the OE group ($P < 0.001$).
  • Follow-up Compliance: The DTD group was far more likely to return for their breath test (81.1% vs. 44.1% in ITT, $P < 0.001$).
  • Eradication Rates: While the DTD group had a much higher eradication rate in the ITT analysis (89.0% vs 59.1%), the Per-Protocol analysis showed no significant difference (95.8% vs 93.8%).
  • The takeaway: The medication works well for everyone if they take it; the DTD model simply ensures that significantly more people actually take it.
  • Safety: There was no significant difference in adverse events (side effects) between the two groups.

Limitations and Future Work

The authors acknowledge several limitations:

  • Smartphone Literacy: The model requires familiarity with smartphones and WeChat, which may exclude older populations or those in lower socioeconomic brackets.
  • Single-Center Study: The results are from one hospital in Nanjing; a multi-center study with a larger, more diverse sample size is needed to validate the findings globally.
  • Antibiotic Sensitivity: The study did not perform drug-sensitivity testing on the patients' specific H. pylori strains, which could influence eradication success regardless of compliance.
  • Future Direction: The researchers suggest this DTD model could be adapted for other chronic diseases that require strict, long-term medication adherence.

Summary updated

Abstract

This study demonstrated the novel application of the DTD model in the treatment of H. pylori infection, which enabled patients to develop habitual medication-taking behaviors without physician intervention.
BibTeX
@inproceedings{yang2023day,
  author = {Zhen Yang and Wenjie Xiong and Ruoyun Yang and Haisheng Qian and Zhiqing He and Meihong Chen and Jiajia Yang and Huaiming Sang and Yan Jin and Xiaobing Xu and Yun Wang and Guoxin Zhang and Feng Ye},
  title = {{A day-to-day management model improves patient compliance to treatment for Helicobacter pylori infection: a prospective, randomized controlled study}},
  booktitle = {Gut},
  year = {2023},
  doi = {10.1186/s13099-023-00556-x},
}
Figure